Development of plasma biomarkers for Alzheimer's disease

Development of plasma biomarkers for Alzheimer's disease - Plasma biomarkers for AD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012629

Enrollment

Registered

2013-12-19

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Alzheimer's disease diagnosed on the criteria proposed by NIH/AA (2011), showing positive amyloid imaging 2. Mild cognitive impairment (MCI) likely due to Alzheimer's disease, showing positive amyloid imaging 3. Cognitively normal state without organic brain lesions Corresponding to any of the above-mentioned criteria

Exclusion criteria

Exclusion criteria: Neuropsycological disorders other than Alzheimer's disease being suspected to causes of the cognitive decline

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity for the diagnosis of Alzheimer's disease and the early detection of preclinical Alzheimer's disease	—

Countries

Japan

Contacts

Public ContactKatsuhiko Yanagisawa

National Center for Geriatrics and Gerontology Center for Development of Advanced Medicine for Dementia

katuhiko@ncgg.go.jp0562-44-6594

Outcome results